BioWorld

Oct. 18, 2006

'Obvious' Buyout: Lilly Paying $2.1B For Cialis Partner ICOS

ICOS Corp., which through a successful joint venture with Eli Lilly and Co. commercialized the erectile dysfunction product Cialis, agreed to be acquired by Lilly in a deal valued at about $2.1 billion. (BioWorld Today) Read More

Roche, InterMune In HCV Deal With $530M Potential

Genzyme Paying $580M For AnorMED; Millennium Blinks

Memory's Phase IIa Study On Hold; Firm Raises $26M

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...